FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
The Food and Drug Administration’s Arthritis Advisory Committee, together with an added complement of dermatologists and gastroenterologists, unanimously recommended during meetings on July 12 and 13...
Source: Hospitalist News - Category: Hospital Management Source Type: research
More News: Arthritis | Dermatology | Enbrel | Gastroenterology | Hospital Management | Hospitalists | Humira | Rheumatology | Skin